{"id":"NCT00451217","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Comparison of Sugammadex (Org 25969) With Neostigmine as Reversal Agents for Rocuronium or Vecuronium at Reappearance of T2 (P05960)","officialTitle":"A Multi -Center Randomized Parallel Group Comparative Active Controlled Safety Assessor Blinded Phase 3a Pivotal Trial in Adult Subjects Comparing Org 25969 With Neostigmine as Reversal Agents of a Neuromuscular Block Induced by Rocuronium or Vecuronium at Reappearance of T2","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-11-17","primaryCompletion":"2006-03-06","completion":"2006-03-06","firstPosted":"2007-03-23","resultsPosted":"2019-02-18","lastUpdate":"2019-03-04"},"enrollment":198,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Anesthesia, General"],"interventions":[{"type":"DRUG","name":"Sugammadex","otherNames":["Org 25969"]},{"type":"DRUG","name":"Neostigmine","otherNames":["premix neostigmine/glycopyrrolate"]}],"arms":[{"label":"Rocuronium + Sugammadex","type":"EXPERIMENTAL"},{"label":"Rocuronium + Neostigmine","type":"ACTIVE_COMPARATOR"},{"label":"Vecuronium + Sugammadex","type":"EXPERIMENTAL"},{"label":"Vecuronium + Neostigmine","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study was to demonstrate in adult participants faster recovery from a neuromuscular block induced by either rocuronium or vecuronium after reversal at reappearance of T2 (the amplitude of the first response of second twitch to train of four (TOF) stimulation, expressed as percentage of control first twitch, T1) by 2.0 mg/kg sugammadex (Org 25969) compared to 50 ug/kg neostigmine.","primaryOutcome":{"measure":"Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9.","timeFrame":"Day 1: From start of sugammadex or neostigmine administration to recovery of T4/T1 ratio to 0.9","effectByArm":[{"arm":"Rocuronium + Sugammadex","deltaMin":1.62,"sd":0.83},{"arm":"Rocuronium + Neostigmine","deltaMin":26.78,"sd":24.6},{"arm":"Vecuronium + Sugammadex","deltaMin":4.47,"sd":9.28},{"arm":"Vecuronium + Neostigmine","deltaMin":23.43,"sd":18.53}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":11},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["19713265","20683334"],"seeAlso":["http://www.merck.com/clinical-trials/policies-perspectives.html"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":48},"commonTop":["Procedural pain","Nausea","Pain","Vomiting","Dry mouth"]}}